Donor PAI-1 expression inhibits the intimal response of early allograft vascular disease

Journal of Heart and Lung Transplantation

Volumn 22, Issue 5, 2003, Pages 515-518

  Benza, Raymond L ^a   Anderson, Peter G ^b   Lyle, Kerry ^a   Barchue, Joseph ^a   De Oliveira, Ana Luna ^a   Cavender, Matthew A ^a   Pinderski, Laura J ^a   George, James F ^c  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c Kentucky   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OKT 4; OKT 8; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ABDOMINAL AORTA; ALLOGRAFT VASCULAR DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA GRAFT; ARTERY INTIMA PROLIFERATION; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; KNOCKOUT MOUSE; MALE; MATHEMATICAL COMPUTING; MORPHOMETRICS; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASCULAR DISEASE;

EID: 0037991438     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1053-2498(02)00662-9     Document Type: Article

References (30)

1. Labarrere C.A., Pitts D., Halbrook H., Faulk W.P. Natural anticoagulant pathways in normal and transplanted human hearts. J Heart Lung Transplant. 11:1992;342-347.
2. Labarrere C.A., Nelson D.R., Faulk W.P. Myocardial fibrin deposits in the first month after transplantation predict subsequent coronary artery disease and graft failure in cardiac allograft recipients. Am J Med. 105:1998;207-213.
3. Labarrere C.A., Pitts D., Nelson D.R., Faulk W.P. Vascular tissue plasminogen activator and the development of coronary artery disease in heart-transplantation recipients. N Engl J Med. 333:1995;1111-1116.
4. Hunt B.J., Segal H., Yacoub M. Hemostatic changes in heart transplant recipients and their relationship to accelerated coronary sclerosis. Transplantation. 55:1993;309-315.
5. Warshofsky M.K., Wasserman H.S., Wang W., et al. Plasma levels of tissue plasminogen activator and plasminogen activator inhibitor-1 are correlated with the presence of transplant coronary artery disease in cardiac transplant recipients. Am J Cardiol. 80:1997;145-149.
6. Carmeliet P., Collen D. Role of plasminogen/plasmin system in thrombosis, hemostasis, restenosis and atherosclerosis evaluation in transgenic animals. Trends Cardiovasc Med. 5:1995;117-122.
7. Reidy M.A., Irvin C., Lindner V. Migration of arterial wall cells expression of plasminogen activators and inhibitors in injured rat arteries. Circ Res. 78:1996;405-414.
8. Carmeliet P., Moons L., Ploplis V.A., Plow E., Collen D. Impaired arterial neointima formation in mice with disruption of the plasminogen gene. J Clin Invest. 99:1997;200-208.
9. Xiaoli M., Wenying H., Mingpeng S. Effects of mechanism of tissue-type plasminogen activator and plasminogen activator inhibitor on vascular smooth muscle cell proliferation. Int J Cardiol. 66:(suppl):1998;S57-64.
10. Carmeliet P., Moons L., Lijnen R., et al. Inhibitor role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation a gene targeting and gene transfer study in mice. Circulation. 96:1997;3180-3191.
11. Jackson C.L., Reidy M.A. The role of plasminogen activation in smooth muscle cell migration after arterial injury. Ann NY Acad Sci. 667:1992;141-150.
12. Chow L.H., Huh S., Jiang J., Zhong R., Pickering J.G. Intimal thickening develops without humoral immunity in a mouse aortic allograft model of chronic vascular rejection. Circulation. 94:1996;3079-3082.
13. Koglin J., Glysing-Jensen T., Mudgett J.S., Russell M.E. Exacerbated transplant arteriosclerosis in inducible nitric oxide-deficient mice. Circulation. 97:1998;2059-2065.
14. Koulack J., McAlister M.B., Giacomantonio C.A., Bitter-Suermann H., Lee T.G. Development of a mouse aortic transplant model of chronic rejection. Microsurgery. 16:1995;110-113.
15. Mennander A., Tilsala S., Halttunen J., Yilmaz S., Paavonen T., Hayry P. Chronic rejection in rat aortic allografts an experimental model for transplantation arteriosclerosis. Arterioscler Thromb. 11:1991;671-680.
16. Johnson D.E., Gao S.-Z., Schroeder J.S., DeCampli W.M., Billingham M.E. The spectrum of coronary artery pathologic findings in human cardiac allografts. J Heart Transplant. 8:1989;349-359.
17. Bieber C.P., Stinson E.B., Shumway N.E., Payne R., Kosek J. Cardiac transplantation in man. VII. Cardiac allograft pathology. Circulation. 61:1970;753-772.
18. Billingham M.E. Cardiac transplant atherosclerosis. Transplant Proc. 19:1987;19-25.
19. Billingham M.E. Pathology of graft vascular disease after heart and heart-lung transplantation and its relationship to obliterative bronchiolitis. Transplant Proc. 27:1995;2013-2016.
20. Uys C.J., Rose A.G. Pathologic findings in long-term cardiac transplants. Arch Pathol Lab Med. 108:1984;112-116.
21. Hamsten A., Blomback M., Wiman B., et al. Haemostatic function in myocardial infarction. Br Heart J. 55:1986;58-66.
22. Schwartz C.J., Valente A.J., Kelley J.L., Sprague E.A., Edwards E.H. Thrombosis and the development of atherosclerosis Rokitansky revisited. (review) Semin Thromb Hematol. 14:1988;189-195.
23. Padro T., Emeis J.J., Steins M., Schmid K.W., Kienast J. Quantification of plasminogen activators and their inhibitors in the aortic vessel wall in relation to the presence and severity of atherosclerotic disease. Arterioscler Thromb Vasc Biol. 15:1995;893-902.
24. Benza R.L., Grenett H.E., Bourge R.C., et al. Gene polymorphisms for plasminogen activator inhibitor-1/tissue plasminogen activator and development of allograft coronary artery disease. Circulation. 98:1998;2248-2254.
25. Sawa H., Lundgren C.H., Sobel B.E., Fujii S. Increased intramural expression of plasminogen activator inhibitor type 1 after balloon injury a potential progenitor of restenosis. J Am Coll Cardiol. 24:1994;1742-1748.
26. Smith E.B., Thompson W.D. Fibrin as a factor in atherogenesis. Thromb Res. 73:1994;1-19.
27. Juhan-Vague I., Alessi M.C. Plasminogen activator inhibitor 1 and atherothrombosis. Thromb Haemost. 70:1993;138-143.
28. Meade T.W., Chakrabarti R., Haines A.P., North W.F., Stirling Y. Characteristics affecting fibrinolytic activity and plasma fibrinogen concentrations. BMJ. 1:1979;153-156.
29. Andersen P., Arnesen H., Hjermann I. Hyperlipoproteinaemia and reduced fibrinolytic activity in healthy coronary high-risk men. Acta Med Scand. 209:1981;199-202.
30. Lupu F., Bergonzelli G.E., Heim D., et al. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb. 13:1993;1090-1100.